PINEBIOAnalytics for molecular data in healthcare

CLINICAL DATA

GENOMICS

TRANSCRIPTOMICS

MICROBIOME

PROTEOMICS

EPIGENETICS

disease symptoms

CANCERwill this affect my family?how long do I have?what exactly is going on?what is the best treatment?

1,600,000People die from cancer every

year in the US alone…

24%relapse or exhaust standard of care

radiologist

medical oncologist

surgical oncologist

patient

pathologist

drug interactions

clinical trials

co-morbidities

epigenetic biomarkers

circulating tumor cells

copy number variation

new screens

combination therapies

resistance development

cfDNA markers

micro biome variation

PERSONALIZED CARE

PRECISION INSIGHT

data aggregation better decisions

PINEBIO

research and discovery molecular diagnostics

ANALYTICAL DASHBOARDS

PERSONALIZED CLINICAL INTERFACE

POWERFUL DATA ANALYSIS ENVIRONMENT

PROTEIN-DRUG INTERACTIONS

STRUCTURALSCREENING

MUTATION ANALYSIS

12

3

ACADEMIC HOSPITALS PHARMA COMPANIES

BUSINESS MODEL

SAAS LICENSE SERVICES DATA+ +

RESEARCH TEAMS

less headaches for doctors

more options for

patients

DR. ALFRED TAUBER DR. LEONID BRODSKYEstablished one of the first bioinformatics labs at Lomonosov Moscow State University in 1989. Dr. Leonid Brodsky has been leading bioinformatics research, computational biology and systems biology modeling for over 30 years. His expertise and methods contributed to numerous scientific discoveries and publications. Currently, he is a Senior Reseach associate, and the Director of the Tauber Bioinformatics Research Center in University of Haifa

Zoltan Kohn Professor Emeritus of Medicine at Boston University. Originally trained as a biochemist and hematologist. Aside from over 125 research publications in

biochemistry and cell biology, Tauber has published extensively on 19th and 20th century biomedicine, the development of modern immunology, the doctor-patient

relationship, and contemporary science studies. In 2013 Tauber was appointed Chairman of the Board of Governors of the University of Haifa.

COMPANY FOUNDERS

CORE TEAM

ELIA BRODSKY AVI TITIEVSKY PRIYAL DE ZOYSAJACLYN WILLIAMS

Harvard Business School HBX CORe, Bar Ilan Applied

Mathematics, BA in Visual Communications and

Marketing. A number of previous startups as founder

or co-founder.

MS in Computer Science and Ph.D. candidate in Machine

Learning for Systems Engineering. Has been

working closely with TBRC for the past 6 years at Haifa

University.

MS in Microbiology from University of South

Mississippi. Experience in lab management, genomics and bioinformatics and several

publications in microbiology.

Background in big Pharma and tech companies such as

Seven Bridges, Life technologies. Ph.D. in

BioScience and Biotechnology.

TRACTION & MILESTONES:

in October 2016, our multi-omics platform was awarded

the grand prize of $20,000 in a startup competition organized

by the Pistoia Alliance, a professional organization that brings together big Pharma

and tech companies

Starting in March 2017, our team is collaborating on a DARPA-

funded projects with researchers from University of San Francisco, Boston University, CDC, IBM and others. This a multi-million dollar project seeks to develop a new

therapeutic for infectious diseases.

For the past several months, our team has participated in a number of business accelerator programs, including the Propeller Health Accelerator and the CAPITALx program run by the Idea

Village. These programs and the team at the New Orleans BioInnovation Center are helping prepare our company for growth.

VALIDATION PROJECTS AND EARLY ADOPTERS:

LOW FREQUENCY MUTATION DETECTION IN VIROLOGY: COLLABORATION WITH UCSF, STANFORD AND OTHERS TO DEVELOP A METHOD OF HOST-PATHOGEN INTERACTIONS USING ULTRA DEEP SEQUENCING.

DARPA INTERCEPT PROGRAM:WORKING WITH RESEARCH AND MODELING TEAMS FROM UCSF, BU, STANFORD AND IBM AS A DATA ANALYTICS AND MANAGEMENT PLATFORM PROVIDER. THE OBJECTIVE OF THE PROJECT IS DEVELOPMENT OF NEW THERAPEUTICS

CLINICAL TRIALS DATA:WORKING ON A CLINICAL TRIAL DATASET FOR ACCORD THERAPEUTICS TO IDENTIFY BIOMARKERS FOR DRUG RESPONSE

CLINICAL CANCER STUDIES:A NUMBER OF VALIDATION PROJECTS WITH RESEARCHERS AT LSU HEALTH SCIENCES AND TULANE MEDICAL SCHOOL TO DEVELOP EFFECTIVE WORKFLOWS AROUND EARLY DETECTION OF PATIENTS WHERE MOLECULAR INSIGHT CAN LEAD TO MORE EFFECTIVE TREATMENTS

BASIC RESEARCH PROJECTS:COLLABORATION WITH A NUMBER OF RESEARCHERS ON TARGET DISCOVERY AND ANALYSIS OF MULTI-OMICS DATASETS FOR PLATFORM DEVELOPMENT AND REFINEMENT

OCT. 2015 DEC. 2015 JULY. 2016 MARCH. 2017 APRIL. 2017

elia@pine.bio